SCHEMBL2467170

SCHEMBL2467170

Cc1cc(Nc2ncc(-c3n[nH]c4c(F)cccc34)c(N)n2)cc(S(C)(=O)=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 5/20 0.39
CCNT1 O60563 4/20 0.39
CDK9 P50750 4/20 0.39
CCNE1 P24864 4/20 0.39
CDK1 P06493 3/20 0.39
CCNB1 P14635 3/20 0.39
CCNA2 P20248 2/20 0.39
CDK7 P50613 2/20 0.39
CCNH P51946 2/20 0.39
PTGS2 P35354 1/20 0.38
PTK6 Q13882 2/20 0.38
LCK P06239 1/20 0.38
SYK P43405 1/20 0.38
CCNE2 O96020 3/20 0.36
CCNB2 O95067 2/20 0.36
CCNB3 Q8WWL7 2/20 0.36
CCNA1 P78396 1/20 0.36
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14634093 0.90 CDK2 (0.41) CDK2CCNT1CDK9CCNE1CDK1
SCHEMBL2466508 0.89 CDK9 (0.40) CDK2CCNT1CDK9CCNE1CDK1
SCHEMBL14634077 0.89 JAK1 (0.40) CDK2CCNT1CDK9CCNE1CDK1
SCHEMBL14633978 0.85 EPHB4 (0.41) CDK2CCNT1CDK9CCNE1CDK1
SCHEMBL2468378 0.85 CDK1 (0.39) CDK2CCNT1CDK9CDK1CCNB1
SCHEMBL2468102 0.85 CDK2 (0.39) CDK2CCNT1CDK9CCNE1CDK1
SCHEMBL2471505 0.83 RIPK2 (0.42) CDK2CCNT1CDK9CCNE1PTGS2
SCHEMBL14633684 0.82 ITK (0.37) CDK2CCNT1CDK9CCNE1PTGS2
SCHEMBL2468605 0.80 PTGS2 (0.39) PTGS2PTK6LCK
SCHEMBL2466342 0.79 CDK9 (0.40) CDK2CCNT1CDK9CCNE1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
EP-2552211-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-02-06 EP disclosed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed
WO-2011120025-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 CDK2 22/4885CCNT1 331/4885CDK9 55/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 CDK2 1/4885CCNT1 282/4885CDK9 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.